# The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment

> **NCT04984369** · PHASE2 · UNKNOWN · sponsor: **Shanghai Henlius Biotech** · enrollment: 50 (estimated)

## Conditions studied

- CRC

## Interventions

- **DRUG:** HLX208
- **DRUG:** Cetuximab Injection [Erbitux]

## Key facts

- **NCT ID:** NCT04984369
- **Lead sponsor:** Shanghai Henlius Biotech
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2021-08-11
- **Primary completion:** 2024-06-15
- **Final completion:** 2025-01-15
- **Target enrollment:** 50 (ESTIMATED)
- **Last updated:** 2023-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04984369

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04984369, "The Efficacy of HLX208 (BRAF V600E Inhibitor) With Cetuximab for Metastatic Colorectal Cancer (mCRC) With BRAF V600E Mutation After First-line Treatment". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04984369. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*